Assessment of the anti-biofilm activity of an anti-infective molecule

Background of in vitro-biofilm

•    Biofilm is a three-dimensional community of bacteria with intricate architecture that lives on surfaces and is encapsulated in a network of hydrated polysaccharides, proteins and DNA

•    The biofilm state appears to be natural and predominant state of bacteria
•    The biofilms are responsible for causing a broad range of chronic diseases
•    Bacterial biofilms significantly enhance antibiotic resistance by inhibiting the penetration of antibiotics, resulting in an increasingly serious situation
•    A major focus is being put on various anti-biofilm molecules

Objectives of the model

•    To determine the anti-biofilm activity of a molecule using an in vitro model of biofilm formed by Staphylococcus aureus MRSA

Our approach at Vibiosphen 
•    Microplate wells were seeded by S. aureus for 24h or 48h to allow biofilm formation 
•    A range of concentrations of the molecule was applied on the biofilm, in triplicate for 24h
•    The biofilm density was quantified with crystal violet staining

Outcomes of in vitro-biofilm

 Saureus biofilm formed on an abiotic surface and stained with    crystal violet

Quantification of S. aureus biofilm subsequently to a 24h treatment with increasing amounts of the molecule

•    These results support the molecule as a novel drug candidate and an effective treatment strategy for Staphylococcus aureus biofilm-associated infections
•    A possible application of this discovery could lie in methods of inhibiting bacterial adhesion on medical implants/device.

Why Choose Vibiosphen?

•    Proven expertise in preclinical research
•    Flexible and customized study designs adapted to sponsor requirements (see downloads available as example) 
•    Advanced facilities to ensure reliable and reproducible results (BSL2 and BSL3) 
•    Strong collaborations with pharmaceutical companies, biotech firms, and academic partners
Vibiosphen combines scientific excellence with industry know-how to deliver actionable preclinical data that drive innovation in infectious disease therapeutics.
 

Contact Us

If you are developing new treatments or vaccines, Vibiosphen can help accelerate your research.
Contact us today to discuss your project and explore how our Pharmacokinetics models can support your development strategy. 
We will be pleased to facilitate your project by providing a customized study design to your project objectives.